SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Domingos Joana) "

Search: WFRF:(Domingos Joana)

  • Result 1-2 of 2
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Kehoe, Laura, et al. (author)
  • Make EU trade with Brazil sustainable
  • 2019
  • In: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341-
  • Journal article (other academic/artistic)
  •  
2.
  • Previtali, Stefano C., et al. (author)
  • Rimeporide as a first- in-class NHE-1 inhibitor : Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
  • 2020
  • In: Pharmacological Research. - : Elsevier BV. - 1043-6618 .- 1096-1186. ; 159
  • Journal article (peer-reviewed)abstract
    • Rimeporide, a first-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysiological mechanisms in Congestive Heart Failure (CHF) and in cardiomyopathy in DMD, therefore NHE-1 inhibition could be a promising pharmacological approach to the cardiac dysfunctions observed in DMD. Extensive preclinical data was collected in various animal models including dystrophin-deficient (mdx) mice to characterise Rimeporide's anti-fibrotic and anti-inflammatory properties and there is evidence that NHE-1 inhibitors could play a significant role in modifying DMD cardiac and also skeletal pathologies, as the NHE-1 isoform is ubiquitous. We report here the first study with Rimeporide in DMD patients. This 4-week treatment, open label phase Ib, multiple oral ascending dose study, enrolled 20 ambulant boys with DMD (6-11 years), with outcomes including safety, pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers. Rimeporide was safe and well-tolerated at all doses. PK evaluations showed that Rimeporide was well absorbed orally reaching pharmacological concentrations from the lowest dose, with exposure increasing linearly with dose and with no evidence of accumulation upon repeated dosing. Exploratory PD biomarkers showed positive effect upon a 4-week treatment, supporting its therapeutic potential in patients with DMD, primarily as a cardioprotective treatment, and provide rationale for further efficacy studies.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-2 of 2
Type of publication
journal article (2)
Type of content
other academic/artistic (1)
peer-reviewed (1)
Author/Editor
Al-Khalili Szigyarto ... (1)
Rothhaupt, Karl-Otto (1)
Weigend, Maximilian (1)
Farrell, Katharine N ... (1)
Islar, Mine (1)
Krause, Torsten (1)
show more...
Uddling, Johan, 1972 (1)
Alexanderson, Helena (1)
Schneider, Christoph (1)
Battiston, Roberto (1)
Lukic, Marko (1)
Pereira, Laura (1)
Riggi, Laura (1)
Cattaneo, Claudio (1)
Jung, Martin (1)
Andresen, Louise C. (1)
Kasimir, Åsa (1)
Johansson, Camilla (1)
Wang-Erlandsson, Lan (1)
Sutherland, William ... (1)
Boonstra, Wiebren J. (1)
Vajda, Vivi (1)
Pascual, Unai (1)
Tscharntke, Teja (1)
Brown, Calum (1)
Peterson, Gustaf (1)
Meyer, Carsten (1)
Seppelt, Ralf (1)
Johansson, Maria (1)
Martin, Jean Louis (1)
Olsson, Urban (1)
Hortal, Joaquin (1)
Buckley, Yvonne (1)
Petrovan, Silviu (1)
Schindler, Stefan (1)
Carvalho, Joana (1)
Amo, Luisa (1)
Machordom, Annie (1)
De Smedt, Pallieter (1)
Lindkvist, Emilie (1)
Matos-Maraví, Pável (1)
Bacon, Christine D. (1)
Silvestro, Daniele (1)
Mascarenhas, André (1)
McPhearson, Timon (1)
Tengö, Maria (1)
Morales, Manuel B. (1)
Müller, Jörg (1)
Kanka, Robert (1)
Muntoni, Francesco (1)
show less...
University
Royal Institute of Technology (2)
Lund University (1)
Mid Sweden University (1)
Chalmers University of Technology (1)
Swedish University of Agricultural Sciences (1)
Language
English (2)
Research subject (UKÄ/SCB)
Natural sciences (1)
Engineering and Technology (1)
Medical and Health Sciences (1)
Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view